1177.HK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 13:38):

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...

Stats
आज की मात्रा	39.49M
औसत मात्रा	52.37M
बाजार मूल्य	50.97B
EPS	HKD0 ( 2024-03-29 )
अगली कमाई की तारीख	( HKD0 ) 2024-06-14
Last Dividend	HKD0.0600 ( 2023-06-20 )
Next Dividend	HKD0 ( N/A )
P/E	25.18
ATR14	HKD0.00800 (0.29%)

मात्रा सहसंबंध

लंबा: 0.02 (neutral)

छोटा: 0.62 (weak)

Signal:(41.732) Neutral

Sino Biopharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Sino Biopharmaceutical सहसंबंध - मुद्रा/वस्त्र

-0.69
( moderate negative )

-0.72
( moderate negative )

0.00
( neutral )

0.58
( weak )

Sino Biopharmaceutical वित्तीय

Annual	2023
राजस्व:	HKD26.20B
सकल लाभ:	HKD21.21B (80.95 %)
EPS:	HKD0.0997

FY	2023
राजस्व:	HKD26.20B
सकल लाभ:	HKD21.21B (80.95 %)
EPS:	HKD0.0997

FY	2022
राजस्व:	HKD28.78B
सकल लाभ:	HKD22.98B (79.86 %)
EPS:	HKD0.270

FY	2021
राजस्व:	HKD26.86B
सकल लाभ:	HKD21.53B (80.15 %)
EPS:	HKD0.780

Financial Reports:

No articles found.

Sino Biopharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0600 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0600 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Sino Biopharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.59 - good (95.94%) | Divividend Growth Potential Score: 5.14 - Stable (2.85%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.00198	2004-09-16
Last Dividend	HKD0.0600	2023-06-20
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	70	--
Total Paid Out	HKD0.573	--
Avg. Dividend % Per Year	0.00%	--
Score	3.91	--
Div. Sustainability Score	9.59
Div.Growth Potential Score	5.14
Div. Directional Score	7.37	--

Next Divdend (Est)
(2024-08-29)

HKD0 Estimate 4.19 %

Dividend Stability

0.34 Poor

Dividend Score

3.91

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6939.HK	Ex Dividend Knight	2023-06-14	Annually	0.00%
1983.HK	Ex Dividend Junior	2023-10-17	Sporadic	0.00%
1052.HK	Ex Dividend Junior	2023-11-03	Annually	0.00%
0133.HK	Ex Dividend Junior	2023-06-01	Annually	0.00%
3600.HK	Ex Dividend Knight	2023-09-12	Annually	0.00%
1600.HK	Ex Dividend Knight	2023-10-24	Semi-Annually	0.00%
0656.HK	Ex Dividend Junior	2023-06-14	Annually	0.00%
9979.HK	Ex Dividend Knight	2023-07-11	Semi-Annually	0.00%
2189.HK	Ex Dividend Knight	2023-08-16	Semi-Annually	0.00%
1186.HK	Ex Dividend Junior	2023-07-25	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0711	1.500	8.58	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0247	1.200	9.18	10.00	[0 - 0.3]
returnOnEquityTTM	0.0519	1.500	-0.534	-0.801	[0.1 - 1]
payoutRatioTTM	0.404	-1.000	5.96	-5.96	[0 - 1]
currentRatioTTM	1.053	0.800	9.73	7.79	[1 - 3]
quickRatioTTM	0.755	0.800	-0.263	-0.210	[0.8 - 2.5]
cashRatioTTM	0.418	1.500	8.79	10.00	[0.2 - 2]
debtRatioTTM	0.197	-1.500	6.72	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.196	2.00	9.93	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.142	2.00	9.93	10.00	[0 - 20]
debtEquityRatioTTM	0.410	-1.500	8.36	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.788	1.000	0.197	0.197	[0.2 - 0.8]
operatingProfitMarginTTM	0.203	1.000	7.94	7.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.306	1.000	9.41	9.41	[0.2 - 2]
assetTurnoverTTM	0.347	0.800	-1.020	-0.816	[0.5 - 2]
Total Score				9.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	31.82	1.000	6.89	0	[1 - 100]
returnOnEquityTTM	0.0519	2.50	-0.343	-0.801	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.142	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	3.12	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.196	2.00	9.93	10.00	[0 - 30]
payoutRatioTTM	0.404	1.500	5.96	-5.96	[0 - 1]
pegRatioTTM	0.329	1.500	-1.141	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.174	1.000	8.16	0	[0.1 - 0.5]
Total Score				5.14

Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.